Register

Pediatric Oncology

ASTRO Journal Club   

Journal Club Q&A done in partnership with ASTRO

Questions discussed in this category



Papers discussed in this category

Blood Adv,
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
Radiother Oncol, 2021 Dec 7
Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?
Int J Radiat Oncol Biol Phys, 2021 Dec 1
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy.
Int J Radiat Oncol Biol Phys, 2022 Dec 20
Don't put the CART before the horse: The role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma.
Transplant Cell Ther, 2022 Dec 30
Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.
Blood advances, 2020 Jul 28
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2022 Oct 26
Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed/refractory aggressive B-cell lymphoma.
Blood advances, 2020 Nov 24
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
J Hematol Oncol, 2022 Mar 26
Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT.
Blood advances, 2022 May 10
Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy.

Related Topics in Pediatric Oncology

Copyright © 2024 theMednet
All Rights Reserved.